0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Malignant Pleural Mesothelioma Treatment Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-36S13467
Home | Market Reports | Health| Health Conditions| Cancer
Global Malignant Pleural Mesothelioma Treatment Market Research Report 2023
BUY CHAPTERS

Global Malignant Pleural Mesothelioma Treatment Market Research Report 2025

Code: QYRE-Auto-36S13467
Report
July 2025
Pages:88
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Malignant Pleural Mesothelioma Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Malignant Pleural Mesothelioma Treatment Market

Malignant Pleural Mesothelioma Treatment Market

The global market for Malignant Pleural Mesothelioma Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Malignant pleural mesothelioma (MPM) is a relatively rare but aggressive form of cancer arising from the membrane covering the lungs and the inner side of the ribs. This type of cancer is most frequently a result of inhaling asbestos.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Malignant Pleural Mesothelioma Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Malignant Pleural Mesothelioma Treatment.
The Malignant Pleural Mesothelioma Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Malignant Pleural Mesothelioma Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Malignant Pleural Mesothelioma Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Malignant Pleural Mesothelioma Treatment Market Report

Report Metric Details
Report Name Malignant Pleural Mesothelioma Treatment Market
CAGR 5%
Segment by Type
Segment by Application
  • Hospitals
  • Clinics
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, Pfizer, Roche, Merck, Ono Pharmaceutical, Mylan, Fresenius Kabi, Sun Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Malignant Pleural Mesothelioma Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Malignant Pleural Mesothelioma Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Malignant Pleural Mesothelioma Treatment Market report?

Ans: The main players in the Malignant Pleural Mesothelioma Treatment Market are Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, Pfizer, Roche, Merck, Ono Pharmaceutical, Mylan, Fresenius Kabi, Sun Pharmaceuticals

What are the Application segmentation covered in the Malignant Pleural Mesothelioma Treatment Market report?

Ans: The Applications covered in the Malignant Pleural Mesothelioma Treatment Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Malignant Pleural Mesothelioma Treatment Market report?

Ans: The Types covered in the Malignant Pleural Mesothelioma Treatment Market report are Pemetrexed, Cisplatin, Others

Recommended Reports

Cancer Drug Therapy

Lung Cancer & Disease

Radiotherapy & Medical Devices

1 Malignant Pleural Mesothelioma Treatment Market Overview
1.1 Product Definition
1.2 Malignant Pleural Mesothelioma Treatment by Type
1.2.1 Global Malignant Pleural Mesothelioma Treatment Market Value Comparison by Type (2024 VS 2031)
1.2.2 Pemetrexed
1.2.3 Cisplatin
1.2.4 Others
1.3 Malignant Pleural Mesothelioma Treatment by Application
1.3.1 Global Malignant Pleural Mesothelioma Treatment Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Malignant Pleural Mesothelioma Treatment Market Size Estimates and Forecasts
1.4.1 Global Malignant Pleural Mesothelioma Treatment Revenue 2020-2031
1.4.2 Global Malignant Pleural Mesothelioma Treatment Sales 2020-2031
1.4.3 Global Malignant Pleural Mesothelioma Treatment Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Malignant Pleural Mesothelioma Treatment Market Competition by Manufacturers
2.1 Global Malignant Pleural Mesothelioma Treatment Sales Market Share by Manufacturers (2020-2025)
2.2 Global Malignant Pleural Mesothelioma Treatment Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Malignant Pleural Mesothelioma Treatment Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Malignant Pleural Mesothelioma Treatment, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Malignant Pleural Mesothelioma Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Malignant Pleural Mesothelioma Treatment, Product Type & Application
2.7 Global Key Manufacturers of Malignant Pleural Mesothelioma Treatment, Date of Enter into This Industry
2.8 Global Malignant Pleural Mesothelioma Treatment Market Competitive Situation and Trends
2.8.1 Global Malignant Pleural Mesothelioma Treatment Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Malignant Pleural Mesothelioma Treatment Players Market Share by Revenue
2.8.3 Global Malignant Pleural Mesothelioma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Malignant Pleural Mesothelioma Treatment Market Scenario by Region
3.1 Global Malignant Pleural Mesothelioma Treatment Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Malignant Pleural Mesothelioma Treatment Sales by Region: 2020-2031
3.2.1 Global Malignant Pleural Mesothelioma Treatment Sales by Region: 2020-2025
3.2.2 Global Malignant Pleural Mesothelioma Treatment Sales by Region: 2026-2031
3.3 Global Malignant Pleural Mesothelioma Treatment Revenue by Region: 2020-2031
3.3.1 Global Malignant Pleural Mesothelioma Treatment Revenue by Region: 2020-2025
3.3.2 Global Malignant Pleural Mesothelioma Treatment Revenue by Region: 2026-2031
3.4 North America Malignant Pleural Mesothelioma Treatment Market Facts & Figures by Country
3.4.1 North America Malignant Pleural Mesothelioma Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Malignant Pleural Mesothelioma Treatment Sales by Country (2020-2031)
3.4.3 North America Malignant Pleural Mesothelioma Treatment Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Malignant Pleural Mesothelioma Treatment Market Facts & Figures by Country
3.5.1 Europe Malignant Pleural Mesothelioma Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Malignant Pleural Mesothelioma Treatment Sales by Country (2020-2031)
3.5.3 Europe Malignant Pleural Mesothelioma Treatment Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Malignant Pleural Mesothelioma Treatment Market Facts & Figures by Region
3.6.1 Asia Pacific Malignant Pleural Mesothelioma Treatment Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Malignant Pleural Mesothelioma Treatment Sales by Region (2020-2031)
3.6.3 Asia Pacific Malignant Pleural Mesothelioma Treatment Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Malignant Pleural Mesothelioma Treatment Market Facts & Figures by Country
3.7.1 Latin America Malignant Pleural Mesothelioma Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Malignant Pleural Mesothelioma Treatment Sales by Country (2020-2031)
3.7.3 Latin America Malignant Pleural Mesothelioma Treatment Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Malignant Pleural Mesothelioma Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa Malignant Pleural Mesothelioma Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Malignant Pleural Mesothelioma Treatment Sales by Country (2020-2031)
3.8.3 Middle East and Africa Malignant Pleural Mesothelioma Treatment Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Malignant Pleural Mesothelioma Treatment Sales by Type (2020-2031)
4.1.1 Global Malignant Pleural Mesothelioma Treatment Sales by Type (2020-2025)
4.1.2 Global Malignant Pleural Mesothelioma Treatment Sales by Type (2026-2031)
4.1.3 Global Malignant Pleural Mesothelioma Treatment Sales Market Share by Type (2020-2031)
4.2 Global Malignant Pleural Mesothelioma Treatment Revenue by Type (2020-2031)
4.2.1 Global Malignant Pleural Mesothelioma Treatment Revenue by Type (2020-2025)
4.2.2 Global Malignant Pleural Mesothelioma Treatment Revenue by Type (2026-2031)
4.2.3 Global Malignant Pleural Mesothelioma Treatment Revenue Market Share by Type (2020-2031)
4.3 Global Malignant Pleural Mesothelioma Treatment Price by Type (2020-2031)
5 Segment by Application
5.1 Global Malignant Pleural Mesothelioma Treatment Sales by Application (2020-2031)
5.1.1 Global Malignant Pleural Mesothelioma Treatment Sales by Application (2020-2025)
5.1.2 Global Malignant Pleural Mesothelioma Treatment Sales by Application (2026-2031)
5.1.3 Global Malignant Pleural Mesothelioma Treatment Sales Market Share by Application (2020-2031)
5.2 Global Malignant Pleural Mesothelioma Treatment Revenue by Application (2020-2031)
5.2.1 Global Malignant Pleural Mesothelioma Treatment Revenue by Application (2020-2025)
5.2.2 Global Malignant Pleural Mesothelioma Treatment Revenue by Application (2026-2031)
5.2.3 Global Malignant Pleural Mesothelioma Treatment Revenue Market Share by Application (2020-2031)
5.3 Global Malignant Pleural Mesothelioma Treatment Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Company Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Eli Lilly Malignant Pleural Mesothelioma Treatment Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 Teva
6.2.1 Teva Company Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Teva Malignant Pleural Mesothelioma Treatment Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Sanofi Malignant Pleural Mesothelioma Treatment Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Bristol-Myers Squibb
6.4.1 Bristol-Myers Squibb Company Information
6.4.2 Bristol-Myers Squibb Description and Business Overview
6.4.3 Bristol-Myers Squibb Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Bristol-Myers Squibb Malignant Pleural Mesothelioma Treatment Product Portfolio
6.4.5 Bristol-Myers Squibb Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Company Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Pfizer Malignant Pleural Mesothelioma Treatment Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Roche
6.6.1 Roche Company Information
6.6.2 Roche Description and Business Overview
6.6.3 Roche Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Roche Malignant Pleural Mesothelioma Treatment Product Portfolio
6.6.5 Roche Recent Developments/Updates
6.7 Merck
6.7.1 Merck Company Information
6.7.2 Merck Description and Business Overview
6.7.3 Merck Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Merck Malignant Pleural Mesothelioma Treatment Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 Ono Pharmaceutical
6.8.1 Ono Pharmaceutical Company Information
6.8.2 Ono Pharmaceutical Description and Business Overview
6.8.3 Ono Pharmaceutical Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Ono Pharmaceutical Malignant Pleural Mesothelioma Treatment Product Portfolio
6.8.5 Ono Pharmaceutical Recent Developments/Updates
6.9 Mylan
6.9.1 Mylan Company Information
6.9.2 Mylan Description and Business Overview
6.9.3 Mylan Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Mylan Malignant Pleural Mesothelioma Treatment Product Portfolio
6.9.5 Mylan Recent Developments/Updates
6.10 Fresenius Kabi
6.10.1 Fresenius Kabi Company Information
6.10.2 Fresenius Kabi Description and Business Overview
6.10.3 Fresenius Kabi Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Fresenius Kabi Malignant Pleural Mesothelioma Treatment Product Portfolio
6.10.5 Fresenius Kabi Recent Developments/Updates
6.11 Sun Pharmaceuticals
6.11.1 Sun Pharmaceuticals Company Information
6.11.2 Sun Pharmaceuticals Description and Business Overview
6.11.3 Sun Pharmaceuticals Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Sun Pharmaceuticals Malignant Pleural Mesothelioma Treatment Product Portfolio
6.11.5 Sun Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Malignant Pleural Mesothelioma Treatment Industry Chain Analysis
7.2 Malignant Pleural Mesothelioma Treatment Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Malignant Pleural Mesothelioma Treatment Production Mode & Process Analysis
7.4 Malignant Pleural Mesothelioma Treatment Sales and Marketing
7.4.1 Malignant Pleural Mesothelioma Treatment Sales Channels
7.4.2 Malignant Pleural Mesothelioma Treatment Distributors
7.5 Malignant Pleural Mesothelioma Treatment Customer Analysis
8 Malignant Pleural Mesothelioma Treatment Market Dynamics
8.1 Malignant Pleural Mesothelioma Treatment Industry Trends
8.2 Malignant Pleural Mesothelioma Treatment Market Drivers
8.3 Malignant Pleural Mesothelioma Treatment Market Challenges
8.4 Malignant Pleural Mesothelioma Treatment Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Malignant Pleural Mesothelioma Treatment Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Malignant Pleural Mesothelioma Treatment Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Malignant Pleural Mesothelioma Treatment Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Malignant Pleural Mesothelioma Treatment Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Malignant Pleural Mesothelioma Treatment Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Malignant Pleural Mesothelioma Treatment Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Malignant Pleural Mesothelioma Treatment Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Malignant Pleural Mesothelioma Treatment Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Malignant Pleural Mesothelioma Treatment, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Malignant Pleural Mesothelioma Treatment, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Malignant Pleural Mesothelioma Treatment, Product Type & Application
 Table 12. Global Key Manufacturers of Malignant Pleural Mesothelioma Treatment, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Malignant Pleural Mesothelioma Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Pleural Mesothelioma Treatment as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Malignant Pleural Mesothelioma Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Malignant Pleural Mesothelioma Treatment Sales by Region (2020-2025) & (K Units)
 Table 18. Global Malignant Pleural Mesothelioma Treatment Sales Market Share by Region (2020-2025)
 Table 19. Global Malignant Pleural Mesothelioma Treatment Sales by Region (2026-2031) & (K Units)
 Table 20. Global Malignant Pleural Mesothelioma Treatment Sales Market Share by Region (2026-2031)
 Table 21. Global Malignant Pleural Mesothelioma Treatment Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Malignant Pleural Mesothelioma Treatment Revenue Market Share by Region (2020-2025)
 Table 23. Global Malignant Pleural Mesothelioma Treatment Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Malignant Pleural Mesothelioma Treatment Revenue Market Share by Region (2026-2031)
 Table 25. North America Malignant Pleural Mesothelioma Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Malignant Pleural Mesothelioma Treatment Sales by Country (2020-2025) & (K Units)
 Table 27. North America Malignant Pleural Mesothelioma Treatment Sales by Country (2026-2031) & (K Units)
 Table 28. North America Malignant Pleural Mesothelioma Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Malignant Pleural Mesothelioma Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Malignant Pleural Mesothelioma Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Malignant Pleural Mesothelioma Treatment Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Malignant Pleural Mesothelioma Treatment Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Malignant Pleural Mesothelioma Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Malignant Pleural Mesothelioma Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Malignant Pleural Mesothelioma Treatment Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Malignant Pleural Mesothelioma Treatment Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Malignant Pleural Mesothelioma Treatment Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Malignant Pleural Mesothelioma Treatment Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Malignant Pleural Mesothelioma Treatment Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Malignant Pleural Mesothelioma Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Malignant Pleural Mesothelioma Treatment Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Malignant Pleural Mesothelioma Treatment Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Malignant Pleural Mesothelioma Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Malignant Pleural Mesothelioma Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Malignant Pleural Mesothelioma Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Malignant Pleural Mesothelioma Treatment Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Malignant Pleural Mesothelioma Treatment Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Malignant Pleural Mesothelioma Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Malignant Pleural Mesothelioma Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Malignant Pleural Mesothelioma Treatment Sales (K Units) by Type (2020-2025)
 Table 51. Global Malignant Pleural Mesothelioma Treatment Sales (K Units) by Type (2026-2031)
 Table 52. Global Malignant Pleural Mesothelioma Treatment Sales Market Share by Type (2020-2025)
 Table 53. Global Malignant Pleural Mesothelioma Treatment Sales Market Share by Type (2026-2031)
 Table 54. Global Malignant Pleural Mesothelioma Treatment Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Malignant Pleural Mesothelioma Treatment Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Malignant Pleural Mesothelioma Treatment Revenue Market Share by Type (2020-2025)
 Table 57. Global Malignant Pleural Mesothelioma Treatment Revenue Market Share by Type (2026-2031)
 Table 58. Global Malignant Pleural Mesothelioma Treatment Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Malignant Pleural Mesothelioma Treatment Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Malignant Pleural Mesothelioma Treatment Sales (K Units) by Application (2020-2025)
 Table 61. Global Malignant Pleural Mesothelioma Treatment Sales (K Units) by Application (2026-2031)
 Table 62. Global Malignant Pleural Mesothelioma Treatment Sales Market Share by Application (2020-2025)
 Table 63. Global Malignant Pleural Mesothelioma Treatment Sales Market Share by Application (2026-2031)
 Table 64. Global Malignant Pleural Mesothelioma Treatment Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Malignant Pleural Mesothelioma Treatment Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Malignant Pleural Mesothelioma Treatment Revenue Market Share by Application (2020-2025)
 Table 67. Global Malignant Pleural Mesothelioma Treatment Revenue Market Share by Application (2026-2031)
 Table 68. Global Malignant Pleural Mesothelioma Treatment Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Malignant Pleural Mesothelioma Treatment Price (US$/Unit) by Application (2026-2031)
 Table 70. Eli Lilly Company Information
 Table 71. Eli Lilly Description and Business Overview
 Table 72. Eli Lilly Malignant Pleural Mesothelioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Eli Lilly Malignant Pleural Mesothelioma Treatment Product
 Table 74. Eli Lilly Recent Developments/Updates
 Table 75. Teva Company Information
 Table 76. Teva Description and Business Overview
 Table 77. Teva Malignant Pleural Mesothelioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Teva Malignant Pleural Mesothelioma Treatment Product
 Table 79. Teva Recent Developments/Updates
 Table 80. Sanofi Company Information
 Table 81. Sanofi Description and Business Overview
 Table 82. Sanofi Malignant Pleural Mesothelioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Sanofi Malignant Pleural Mesothelioma Treatment Product
 Table 84. Sanofi Recent Developments/Updates
 Table 85. Bristol-Myers Squibb Company Information
 Table 86. Bristol-Myers Squibb Description and Business Overview
 Table 87. Bristol-Myers Squibb Malignant Pleural Mesothelioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Bristol-Myers Squibb Malignant Pleural Mesothelioma Treatment Product
 Table 89. Bristol-Myers Squibb Recent Developments/Updates
 Table 90. Pfizer Company Information
 Table 91. Pfizer Description and Business Overview
 Table 92. Pfizer Malignant Pleural Mesothelioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Pfizer Malignant Pleural Mesothelioma Treatment Product
 Table 94. Pfizer Recent Developments/Updates
 Table 95. Roche Company Information
 Table 96. Roche Description and Business Overview
 Table 97. Roche Malignant Pleural Mesothelioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Roche Malignant Pleural Mesothelioma Treatment Product
 Table 99. Roche Recent Developments/Updates
 Table 100. Merck Company Information
 Table 101. Merck Description and Business Overview
 Table 102. Merck Malignant Pleural Mesothelioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Merck Malignant Pleural Mesothelioma Treatment Product
 Table 104. Merck Recent Developments/Updates
 Table 105. Ono Pharmaceutical Company Information
 Table 106. Ono Pharmaceutical Description and Business Overview
 Table 107. Ono Pharmaceutical Malignant Pleural Mesothelioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Ono Pharmaceutical Malignant Pleural Mesothelioma Treatment Product
 Table 109. Ono Pharmaceutical Recent Developments/Updates
 Table 110. Mylan Company Information
 Table 111. Mylan Description and Business Overview
 Table 112. Mylan Malignant Pleural Mesothelioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Mylan Malignant Pleural Mesothelioma Treatment Product
 Table 114. Mylan Recent Developments/Updates
 Table 115. Fresenius Kabi Company Information
 Table 116. Fresenius Kabi Description and Business Overview
 Table 117. Fresenius Kabi Malignant Pleural Mesothelioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Fresenius Kabi Malignant Pleural Mesothelioma Treatment Product
 Table 119. Fresenius Kabi Recent Developments/Updates
 Table 120. Sun Pharmaceuticals Company Information
 Table 121. Sun Pharmaceuticals Description and Business Overview
 Table 122. Sun Pharmaceuticals Malignant Pleural Mesothelioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Sun Pharmaceuticals Malignant Pleural Mesothelioma Treatment Product
 Table 124. Sun Pharmaceuticals Recent Developments/Updates
 Table 125. Key Raw Materials Lists
 Table 126. Raw Materials Key Suppliers Lists
 Table 127. Malignant Pleural Mesothelioma Treatment Distributors List
 Table 128. Malignant Pleural Mesothelioma Treatment Customers List
 Table 129. Malignant Pleural Mesothelioma Treatment Market Trends
 Table 130. Malignant Pleural Mesothelioma Treatment Market Drivers
 Table 131. Malignant Pleural Mesothelioma Treatment Market Challenges
 Table 132. Malignant Pleural Mesothelioma Treatment Market Restraints
 Table 133. Research Programs/Design for This Report
 Table 134. Key Data Information from Secondary Sources
 Table 135. Key Data Information from Primary Sources
 Table 136. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Malignant Pleural Mesothelioma Treatment
 Figure 2. Global Malignant Pleural Mesothelioma Treatment Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Malignant Pleural Mesothelioma Treatment Market Share by Type: 2024 & 2031
 Figure 4. Pemetrexed Product Picture
 Figure 5. Cisplatin Product Picture
 Figure 6. Others Product Picture
 Figure 7. Global Malignant Pleural Mesothelioma Treatment Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Malignant Pleural Mesothelioma Treatment Market Share by Application: 2024 & 2031
 Figure 9. Hospitals
 Figure 10. Clinics
 Figure 11. Others
 Figure 12. Global Malignant Pleural Mesothelioma Treatment Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Malignant Pleural Mesothelioma Treatment Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Malignant Pleural Mesothelioma Treatment Sales (2020-2031) & (K Units)
 Figure 15. Global Malignant Pleural Mesothelioma Treatment Average Price (US$/Unit) & (2020-2031)
 Figure 16. Malignant Pleural Mesothelioma Treatment Report Years Considered
 Figure 17. Malignant Pleural Mesothelioma Treatment Sales Share by Manufacturers in 2024
 Figure 18. Global Malignant Pleural Mesothelioma Treatment Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Malignant Pleural Mesothelioma Treatment Players: Market Share by Revenue in Malignant Pleural Mesothelioma Treatment in 2024
 Figure 20. Malignant Pleural Mesothelioma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Malignant Pleural Mesothelioma Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Malignant Pleural Mesothelioma Treatment Sales Market Share by Country (2020-2031)
 Figure 23. North America Malignant Pleural Mesothelioma Treatment Revenue Market Share by Country (2020-2031)
 Figure 24. U.S. Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Malignant Pleural Mesothelioma Treatment Sales Market Share by Country (2020-2031)
 Figure 27. Europe Malignant Pleural Mesothelioma Treatment Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Malignant Pleural Mesothelioma Treatment Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Malignant Pleural Mesothelioma Treatment Revenue Market Share by Region (2020-2031)
 Figure 35. China Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Taiwan Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Indonesia Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Thailand Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Malaysia Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Philippines Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Latin America Malignant Pleural Mesothelioma Treatment Sales Market Share by Country (2020-2031)
 Figure 46. Latin America Malignant Pleural Mesothelioma Treatment Revenue Market Share by Country (2020-2031)
 Figure 47. Mexico Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Brazil Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Argentina Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Middle East and Africa Malignant Pleural Mesothelioma Treatment Sales Market Share by Country (2020-2031)
 Figure 51. Middle East and Africa Malignant Pleural Mesothelioma Treatment Revenue Market Share by Country (2020-2031)
 Figure 52. Turkey Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. UAE Malignant Pleural Mesothelioma Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Global Sales Market Share of Malignant Pleural Mesothelioma Treatment by Type (2020-2031)
 Figure 56. Global Revenue Market Share of Malignant Pleural Mesothelioma Treatment by Type (2020-2031)
 Figure 57. Global Malignant Pleural Mesothelioma Treatment Price (US$/Unit) by Type (2020-2031)
 Figure 58. Global Sales Market Share of Malignant Pleural Mesothelioma Treatment by Application (2020-2031)
 Figure 59. Global Revenue Market Share of Malignant Pleural Mesothelioma Treatment by Application (2020-2031)
 Figure 60. Global Malignant Pleural Mesothelioma Treatment Price (US$/Unit) by Application (2020-2031)
 Figure 61. Malignant Pleural Mesothelioma Treatment Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

RELATED REPORTS

Global Fixation Device for Radiotherapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4H16852
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Group A Streptococcus for Injection Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-37K16619
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Boron Neutron Capture Therapy System Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30U16301
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Radioactive Glass Microsphere Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-2G16953
Thu Sep 25 00:00:00 UTC 2025

Add to Cart